Absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus (HIV)-positive patients

Journal of Clinical Pharmacology

Volumn 38, Issue 12, 1998, Pages 1122-1128

  Jung, Donald ^a,d   Griffy, Kay ^a   Wong, Rodney ^a   Colburn, Wayne ^b   Hulse, Jim ^c  

^a Roche Global Development   (United States)

^b Harris Laboratory   (United States)

^c Harris Laboratories Inc Lincolnshire   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; GANCICLOVIR; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED;

EID: 0032440699     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Drew WL: Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992;6:194-196.
2. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al for the Syntex Cooperative Oral Ganciclovir Study Group: Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333:615-620.
3. Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA, et al (AIDS Clinical Trials Group, Cytomegalovirus Cooperative Study Group): Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995;171: 1431-1437.
4. Lavelle J, Follansbee, Trapnell CB, Buhles WC, Griffy KG, Jung D, et al: Effect of food on the relative bioavailability of oral ganciclovir. J Clin Pharmacol 1996;36:238-241.
5. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB: Ganciclovir absolute bioavailability after oral administration of two 3,000-mg/d dosing regimens in human immunodeficiency virus-and cytomegalovirus-seropositive patients. Clin Ther 1995; 17:425-432.
6. Laskin OL, Cederberg DM, Mills J, Eron LJ, Mildvan D, Spector SA: Ganciclovir for the treatment and supression of serious infections caused by cytomegalovirus. Am J Med 1987;83:201-207.
7. Rubas W, Jezyk N, Grass G: Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 1993;10:113-118.